Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03212170 · ClinicalTrials.gov registry record · Phase 2
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03212170 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 21 participants.
The verdict
NCT03212170, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive breast cancer. The hypothesis is that FFNP SUVmax from PET/MRI will correlate well against the semi-quantitative PR immunohistochemistry score.
Interventions
- DRUG [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03212170
The ClinicalTrials.gov registry entry for NCT03212170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging is the first listed.
NCT03212170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03212170 about?
NCT03212170 is a clinical study titled "FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer". The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive breast cancer. The hypothesis is that FFNP SUVmax from PET/MRI will correlate well against the semi-quantita...
What is the current status of trial NCT03212170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-12-13. Estimated completion is 2024-11-14.
What interventions are being tested in trial NCT03212170?
The interventions under investigation include: [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging (DRUG).
Who is sponsoring clinical trial NCT03212170?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.